Xtl Biopharmaceuticals Ltd Stock Filter Stocks by Fundamentals
| XTLB Stock | USD 2.10 0.22 11.70% |
XTL Biopharmaceuticals Ltd fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL | Cash and Equivalents |
XTL Biopharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of XTL Biopharmaceutica from analyzing XTL Biopharmaceutica's financial statements. These drivers represent accounts that assess XTL Biopharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XTL Biopharmaceutica's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 69.9K | 156.7K | 170.4K | 66.6K | 5.1M | 5.4M | |
| Enterprise Value | (4.4M) | (3.5M) | (2.8M) | (2.0M) | 3.7M | 3.9M |
XTL Biopharmaceutica ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, XTL Biopharmaceutica's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to XTL Biopharmaceutica's managers, analysts, and investors.Environmental | Governance | Social |
XTL Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 5.45 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 1.92 % | ||||
| Number Of Shares Shorted | 70.82 K | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 3.79 X | ||||
| EBITDA | (764 K) | ||||
| Net Income | (1.78 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 206 K | ||||
| Current Ratio | 31.26 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (707 K) | ||||
| Short Ratio | 3.35 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 30.0 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 10.24 M | ||||
| Total Asset | 2.43 M | ||||
| Retained Earnings | (158.25 M) | ||||
| Working Capital | 1.84 M | ||||
| Current Asset | 3 M | ||||
| Net Asset | 2.43 M |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out XTL Biopharmaceutica Piotroski F Score and XTL Biopharmaceutica Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.